Splash Beverage Group (SBEV) signed an exclusive global licensing agreement with Argent BioPharma for CannEpil, a pharmaceutical-grade cannabinoid therapy targeting drug-resistant epilepsy. The deal supports SBEV’s product pipeline with a potential commercial catalyst, but the announcement provides limited near-term financial details.
Splash Beverage Group (SBEV) signed an exclusive global licensing agreement with Argent BioPharma for CannEpil, a pharmaceutical-grade cannabinoid therapy targeting drug-resistant epilepsy. The deal supports SBEV’s product pipeline with a potential commercial catalyst, but the announcement provides limited near-term financial details.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
